Management of chronic allergic eye disease

Publication
Article
Optometry Times JournalMarch digital edition 2023
Volume 15
Issue 03

Treatment should be adjusted based on disease severity.

Ocular allergies, like systemic allergies, can vary in severity, and medical treatment should be adjusted accordingly.

First-line options such as allergen avoidance, cool compresses, preservative-free lubricating eye drops, and over-the-counter medications like mast-cell stabilizers, antihistamines, and combination eye drops are a reasonable approach to seasonal or intermittent allergic conjunctivitis that responds well to management.1

More severe and recalcitrant cases may require a topical corticosteroid to reduce ocular surface inflammation and symptoms. Although corticosteroids are effective, their long-term use requires caution due to such possible complications as elevated IOP, cataract formation, and increased risk of microbial infection.2

Immunomodulating medications like cyclosporine A and tacrolimus may be used in the long-term for severe and recurrent cases of such allergic eye disease (AED) as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).3 In June 2021, the FDA approved cyclosporine 0.1% (Verkazia; Santen Pharmaceutical) for VKC in adolescents and adults. Protopic (tacrolimus) is FDA approved in the second line for atopic dermatitis. Protopic ointment 0.03% is used in patients aged 2 to 15, and both Protopic ointment 0.03% and 0.1% can be used in those 16 years and older.4 It is important to keep the ointment on the periocular skin and caution patients to avoid getting it in the eyes.

References
  1. Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: a once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence). 2016;7(2):107-114. doi:10.2500/ar.2016.7.0158
  2. Liu S, Saldanha IJ, Abraham AG, et al. Topical corticosteroids for dry eye. Cochrane Database Syst Rev. 2022;10(10):CD015070. doi:10.1002/14651858.CD015070.pub2
  3. Erdinest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol. 2014;14(5):457-463. doi:10.1097/ACI.0000000000000089
  4. FDA. Medication Guide: Protopic. 2006.
Recent Videos
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.
Dr. Lisa Hornick goes over cosmetic habits and digital eye strain factors in OSD
Dr. Justin Schweitzer at AAOpt
Behind the mechanism of action of brimonidine tartrate ophthalmic solution
© 2024 MJH Life Sciences

All rights reserved.